Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECTION phase 3 study of oral Dimebon in mild-to-moderate Alzheimer's disease
NL-OMON33588Phase 3Active, not recruiting
- Sponsor
- Medivation
- Start
- Jan 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latrepirdine in Alzheimer's disease (AD), sponsored by Medivation. Primary endpoints: ADAS-cog change from baseline at Week 26 and CIBIC-plus at Week 26. Started Jan 2009; status: active, not recruiting.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON33588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33588.